Editas Medicine (EDIT) and Genevant Sciences announced that they have entered into a collaboration and nonexclusive license agreement to combine Editas Medicine’s CRISPR Cas12a genome editing systems with Genevant’s proprietary LNP technology in the development of in vivo gene editing medicines directed to two undisclosed targets in Editas’ upregulation strategy. Under the terms of the agreement, Genevant has granted to Editas a nonexclusive worldwide license under certain Genevant LNP technology to exploit mRNA-CRISPR Cas12a-LNP products directed to two undisclosed targets for specified fields. Genevant is eligible to receive up to $238M in upfront and contingent milestone payments, as well as tiered royalties on future product sales.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- MaxCyte appoints Cynthia Collins to board of directors
- Editas Medicine Secures $57M Deal for Gene-Editing Technology
- Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher
- Leerink sees little impact to genetic medicines from Pfizer’s Oxbryta withdrawal
- Editas Medicine initiated with a Buy at JonesResearch